HUTCHMED (China) Ltd is a leading pharmaceutical company based in Hong Kong specializing in developing targeted therapies and immunotherapies for cancer and immunological diseases. With a medium risk ESG score of 28.7, the company has a strong portfolio of cancer drug candidates in global clinical studies. Operating in the Oncology/Immunology and Other Ventures segments, HUTCHMED is committed to environmental sustainability and good governance practices.